TGFB1 and Alzheimer disease: Combination of behavioral, oxidative capacity, molecular and brain histopathological studies are applied in an STZ induced AD like model in rats to explore the possible modulation of downstream TGF-β/p-Smad/p21 signaling pathway, as a novel molecular target of both drugs in the management of AD.